More Beat Up Blue Chips

Recently we highlighted several best-of-breed large capitalization companies that have materially under performed this year. Another three companies are examined below. These are not speculative names. They are not richly valued technology or consumer discretionary stocks either. They have wide defensive moats and should be beneficiary of strong cyclical and secular uptrend. But they under performed enough during 2021 with Read more ➝

To access this post, you must purchase Subscription Plan – AVC Pro.

Beaten Down Blue Chips

Several high quality companies now sell for discounted prices after the strong sell since Thanksgiving. The main US indexes maintain relatively high sales and earnings multiples historically. This masks the damage done to most small stocks and even some blue chip names that most astute investors continually monitor for buying opportunities. We highlight three stocks Read more ➝

To access this post, you must purchase Subscription Plan – AVC Pro.
Pharma Co Stats

Friday Investment Talk: Value Vs Growth, Pharma, Stock Picks

Value stocks have been on a tear, while growth stocks and tech leaders have taken a back seat since late January. This has pressured the overall market indexes, e.g. the S&P 500 and the Nasdaq.  March volatility arrived as promised and next week could exacerbate into more weakness as put-call ratios continue to rise and Read more ➝